Semaglutide vs Tirzepatide

The difference is one receptor, and it shows on the scale. Semaglutide, the drug in Ozempic and Wegovy, works GLP-1 alone: the stomach slows, food noise fades, portions shrink. Tirzepatide, the drug in Mounjaro and Zepbound, works GLP-1 plus GIP, and the pair pulls harder. Run head to head in obesity, each at the top dose people could tolerate, tirzepatide out-lost semaglutide by a clear margin, and both brought the same gut complaints, mostly during the dose climb.

That makes tirzepatide the default, lifters included. For the last few kilos of a diet, its appetite control is firm enough to hold a deficit and loose enough that you can still eat your protein and train. Semaglutide’s case is access and record: the most people studied, the longest approved use, and the cardiovascular outcomes result. If the semaglutide script is the one you can get, take it. If you have a lot to lose and are buying on the gray market anyway, the real question is retatrutide, which out-cuts both. The older pharmacy options, orlistat, Qsymia, and Saxenda, lose to these two on effect.

Day to day, the rhythm is the same: one pin, one day a week, so switching never means relearning a schedule. Both share one catch, too. Stop either and the hunger comes back, and the weight follows it, so plan to come down to a maintenance dose rather than quit cold.

These two have met head to head twice. SURMOUNT-5, in obesity at semaglutide’s weight-loss doses, leads; SURPASS-2 was the diabetes trial; the rest are separate programs:

The method is shared: a weekly sub-q pin, with hunger deciding when to go up. Open on the lowest step, sit there while appetite stays down, and move up only when it truly returns, roughly a month apart. Most people find their number in the lower half of either range. The milligrams do not translate, so never carry a number from one to the other.

Switching from semaglutide to tirzepatide, take the first tirzepatide dose on the day your next semaglutide shot was due. No washout, no overlap. Start at 2.5 mg, or 5 mg if you were holding a high semaglutide dose and want to skip a hungry month; your gut knows GLP-1 already, so the climb usually goes faster than a first-timer’s. Going the other way, usually because the prescription changed, swap on the same day and start semaglutide at 0.5 to 1 mg rather than back at 0.25.

Pick one; never both. Two GLP-1 drugs in one gut means twice the nausea and no shown gain on the scale. If the appetite grip fades on either after months, add a small weekly dose of cagrilintide, a different hunger circuit; semaglutide plus cagrilintide is the pairing in development as CagriSema. I would still start on tirzepatide alone and keep cagrilintide in reserve. Alcohol sits badly on both, since a slowed stomach makes drinks hit harder and nausea arrive faster. Keep protein high and keep lifting the whole way down.

Close to the same gut profile: head to head in obesity, gut effects were the most common complaint on both, mostly mild to moderate and mainly during the dose climb. In the diabetes trial, nausea hit 17% to 22% on tirzepatide and 18% on semaglutide 1 mg: